Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC.
Walsh
Alexandra
A
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kelly
David R
DR
Vaid
Yoginder N
YN
Hilliard
Lee M
LM
Friedman
Gregory K
GK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D002648:Child; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D012805:Sickle Cell Trait / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine